Johns Hopkins-led study shows how bacterial toxin drives colon tumor formation

Myriam Chalabi wins the grand prize for Innovators in Science Award by Takeda and Nature

Takeda and Nature announced the grand prize winner for the 2026 Innovators in Science Award—Myriam Chalabi, a medical oncologist at the Netherlands Cancer Institute.

April 17, 2026

Vol.52 No.15

Clinical Roundup

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

Patients with stage 3 colon cancer with deficient DNA mismatch repair had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq) was added to standard chemotherapy after surgery, according to a study by researchers at the Alliance for Clinical Trials in Oncology.

April 17, 2026

Vol.52 No.15

Clinical Roundup

Johns Hopkins scientists engineer nanoparticles able to seek and destroy diseased immune cells

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can “educate” the immune system to find and destroy disease-causing cells throughout the body.

March 13, 2026

Vol.52 No.10

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment

Vasan Yegnasubramanian, MD, PhD, is the director of Precision inHealth Medicine at Johns Hopkins. He spoke with Johns Hopkins Kimmel Cancer Center communications staff about how AI is transforming cancer research and treatment. The transcript of the conversation follows.

March 06, 2026

Vol.52 No.09

By John’s Hopkins Kimmel Cancer Center Communications

Clinical Roundup

Johns Hopkins investigators create open source database to more easily study cancer data

Researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University have created a novel database structure that allows investigators anywhere to more easily study multiple types of cancer data—including laboratory results, genetic sequencing and imaging data—in one setting.

March 06, 2026

Vol.52 No.09

Clinical Roundup

AI-based liquid biopsy may detect liver fibrosis, cirrhosis, and broader chronic disease signals, Johns Hopkins researchers find

Researchers at the Johns Hopkins Kimmel Cancer Center report that an artificial intelligence-based liquid biopsy test using genome-wide cell-free DNA fragmentation patterns and repeat landscapes can detect early liver fibrosis and cirrhosis, and may also reveal signals of broader chronic disease burden.

March 06, 2026

Vol.52 No.09

Johns Hopkins-led study shows how bacterial toxin drives colon tumor formation

YOU MAY BE INTERESTED IN

Myriam Chalabi wins the grand prize for Innovators in Science Award by Takeda and Nature

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

Johns Hopkins scientists engineer nanoparticles able to seek and destroy diseased immune cells

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment

Johns Hopkins investigators create open source database to more easily study cancer data

AI-based liquid biopsy may detect liver fibrosis, cirrhosis, and broader chronic disease signals, Johns Hopkins researchers find

Renew today!

Subscriber content

Never miss an issue!

Login